Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(112 products)
- CSF-1R(42 products)
- EGFR(572 products)
- Ephrin Receptor(23 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- HER(5 products)
- Hck(3 products)
- IGF-1R(88 products)
- PDGFR(126 products)
- PYK2(7 products)
- Src(79 products)
- TAM Receptor(32 products)
- Tie-2(20 products)
- Trk receptor(59 products)
- Tyrosine Kinases(26 products)
- VEGFR(268 products)
- c-Fms(108 products)
- c-Kit(101 products)
- c-Met/HGFR(128 products)
- c-RET(51 products)
Show 13 more subcategories
Found 1370 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TRK-IN-24
CAS:<p>TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,</p>Formula:C39H45N7O3Purity:98%Color and Shape:SolidMolecular weight:659.82VEGFR-2-IN-37
CAS:<p>VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.</p>Formula:C18H16N2O2SPurity:98%Color and Shape:SolidMolecular weight:324.4BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Formula:C22H15BCl2N2O2Purity:98%Color and Shape:SolidMolecular weight:421.08Cinsebrutinib
CAS:<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Formula:C22H26FN3O2Purity:98%Color and Shape:SolidMolecular weight:383.46FGFR3-IN-7
CAS:<p>FGFR3-IN-7 is a potent, selective inhibitor of FGFR 3, demonstrating an IC50 value of less than 350 nM , and is utilized in cancer research [1].</p>Formula:C25H24FN9OPurity:98%Color and Shape:SolidMolecular weight:485.52Resigratinib
CAS:<p>Resigratinib (KIN-3248) is an oral, irreversible pan-FGFR family protein inhibitor, covalently binds to and inhibits all four FGFR isoforms(FGFR1/2/3/4).</p>Formula:C26H27F2N7O3Purity:98.58%Color and Shape:SolidMolecular weight:523.53Terevalefim
CAS:<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Formula:C9H8N2SPurity:99.8%Color and Shape:SolidMolecular weight:176.24VEGFR2-IN-3
CAS:<p>VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].</p>Formula:C26H28ClN5O4Purity:98%Color and Shape:SolidMolecular weight:509.98ARRY-382
CAS:<p>ARRY-382 is a highly selective oral inhibitor of CSF-1R with an IC50 of 9 nM.</p>Formula:C32H36N8O2Purity:99.76%Color and Shape:SolidMolecular weight:564.68Lifirafenib
CAS:<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Formula:C25H17F3N4O3Purity:98% - 98.25%Color and Shape:SolidMolecular weight:478.42VEGFR-2-IN-9
CAS:<p>VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.</p>Formula:C23H25N3O3Purity:97.19%Color and Shape:SolidMolecular weight:391.46TIE-2/VEGFR-2 kinase-IN-5
CAS:<p>TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.</p>Formula:C21H13F6N5O2Purity:99.79%Color and Shape:SolidMolecular weight:481.35Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formula:C25H26ClFN4O4Purity:99.7%Color and Shape:SolidMolecular weight:500.95EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formula:C34H39ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:632.17PF-06733804
CAS:<p>PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.</p>Formula:C20H19F5N4O4Purity:98%Color and Shape:SolidMolecular weight:474.38PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92CG 428
CAS:<p>CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.</p>Formula:C43H43FN10O6Purity:99.83%Color and Shape:SolidMolecular weight:814.86Edralbrutinib
CAS:<p>Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and</p>Formula:C26H21F2N5O3Purity:99.41%Color and Shape:SolidMolecular weight:489.47TYRA-300
CAS:<p>TYRA-300 is an oral and selective FGFR3 inhibito, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.</p>Formula:C25H24Cl2N6O3SPurity:99.66%Color and Shape:SolidMolecular weight:559.47DYRKs-IN-2
CAS:<p>DYRKs-IN-2 has antitumor activity. DYRKs-IN-2 is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively.</p>Formula:C32H38ClN9O3Purity:98%Color and Shape:SolidMolecular weight:632.16c-met-IN-1
CAS:<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Formula:C35H37FN6O5Purity:98%Color and Shape:SolidMolecular weight:640.7HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formula:C31H29ClFN5O3Purity:99.91%Color and Shape:SolidMolecular weight:574.05BMX-IN-1
CAS:<p>BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine</p>Formula:C29H24N4O4SPurity:98.38%Color and Shape:SolidMolecular weight:524.59PF-06250112
CAS:<p>PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.</p>Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01ALK-IN-27
CAS:<p>Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.</p>Formula:C23H22ClFN6OPurity:99.71%Color and Shape:SolidMolecular weight:452.91FIIN-1
CAS:<p>FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3,</p>Formula:C32H39Cl2N7O4Purity:98.75%Color and Shape:SolidMolecular weight:656.6EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Formula:C28H31ClN6O4Purity:99.16%Color and Shape:SolidMolecular weight:551.04TAK-020
CAS:<p>TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.</p>Formula:C18H17N5O3Purity:98.79%Color and Shape:SolidMolecular weight:351.36BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formula:C24H31N5O4Purity:96.74%Color and Shape:SolidMolecular weight:453.53WAY-600
CAS:<p>WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308).</p>Formula:C28H30N8OPurity:99.88%Color and Shape:SolidMolecular weight:494.59Tyrphostin AG 538
CAS:<p>Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.</p>Formula:C16H11NO5Purity:98.75%Color and Shape:SoildMolecular weight:297.26MK-2461
CAS:<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Formula:C24H25N5O5SPurity:95.41% - 99.53%Color and Shape:SolidMolecular weight:495.55Ropsacitinib
CAS:<p>Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).</p>Formula:C20H17N9Purity:99.87%Color and Shape:SolidMolecular weight:383.41BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Formula:C24H23FN8O2Purity:98.24% - 98.91%Color and Shape:SolidMolecular weight:474.49Zidesamtinib
CAS:<p>Zidesamtinib (NVL-520) is a ROS1 fusion and resistance mutation inhibitor that inhibits ROS1 and can be used to study non-small cell lung cancer.</p>Formula:C22H22FN7OPurity:99.74%Color and Shape:SolidMolecular weight:419.455CH6953755
CAS:<p>CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.</p>Formula:C26H22F2N6O4SPurity:98.03%Color and Shape:SolidMolecular weight:552.55EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formula:C23H15ClFN3OS2Purity:98.93%Color and Shape:SolidMolecular weight:467.97EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93Src Inhibitor 3
CAS:<p>Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.</p>Formula:C34H32ClFN8O4Purity:98.35%Color and Shape:SolidMolecular weight:671.12AZ-23
CAS:<p>AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.</p>Formula:C17H19ClFN7OPurity:99.4%Color and Shape:SolidMolecular weight:391.83EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formula:C32H23ClF3N7O4Purity:99.51%Color and Shape:SolidMolecular weight:662.02HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447Tyrphostin 63
CAS:<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Formula:C10H8N2OColor and Shape:SolidMolecular weight:172.183Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formula:C24H24Br2ClN9O3Purity:99.52%Color and Shape:SolidMolecular weight:681.77TrkA-IN-9
CAS:<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Formula:C31H32N4O4Color and Shape:SolidMolecular weight:524.61FMP-API-1
CAS:<p>FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).</p>Formula:C13H14N2O2Color and Shape:SolidMolecular weight:230.262DDR1-IN-8
CAS:<p>DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.</p>Formula:C23H24F3N5O2Molecular weight:459.46TrkC-IN-1
CAS:<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formula:C28H20BrN5O2Color and Shape:SolidMolecular weight:538.395TrkA-IN-8
CAS:<p>TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.</p>Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368IGF-1R inhibitor-4
CAS:<p>IGF-1Rinhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, demonstrating an inhibition rate of 63% at a concentration of 10 μM. This compound plays a significant role in cancer research.</p>Formula:C13H15ClN4OColor and Shape:SolidMolecular weight:278.737Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669FGFR4-IN-4
CAS:<p>FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.</p>Formula:C28H32Cl2N6O5Purity:98%Color and Shape:SolidMolecular weight:603.5EGFR-IN-139
CAS:<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Formula:C27H25ClN2O4Color and Shape:SolidMolecular weight:476.951GENZ-882706
CAS:<p>GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.</p>Formula:C26H25N5O3Purity:98%Color and Shape:SolidMolecular weight:455.51ITK inhibitor 2
CAS:<p>ITK inhibitor 2 (compound 4) is a potent and selective ITK inhibitor with an IC50= 2 nM.</p>Formula:C25H33N5O2Purity:99.67%Color and Shape:SolidMolecular weight:435.56Pimicotinib hydrochloride
CAS:<p>Pimicotinib hydrochloride is an inhibitor of CSF1R, displaying antitumor activity.</p>Formula:C22H25ClN6O3Color and Shape:SolidMolecular weight:456.925DYR530
CAS:<p>DYR530 is a ligand for the target protein (protein kinase DYRK1A) of PROTAC.</p>Formula:C23H24FN7Color and Shape:SolidMolecular weight:417.48CGP062464
CAS:<p>CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.</p>Formula:C18H14N4Color and Shape:SolidMolecular weight:286.331NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Formula:C28H30Cl2F2N6O4Color and Shape:SolidMolecular weight:623.48Enrupatinib
CAS:<p>Enrupatinib is an inhibitor of the colony stimulating factor 1 receptor (CSF1R), exhibiting antitumor activity.</p>Formula:C27H26N6O3Color and Shape:SolidMolecular weight:482.53EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formula:C16H15N3OSColor and Shape:SolidMolecular weight:297.375EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57c-Met-IN-26
CAS:c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Formula:C24H19F2N9Color and Shape:SolidMolecular weight:471.46Fanregratinib
CAS:Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.Formula:C27H33ClN6O2Color and Shape:SolidMolecular weight:509.04HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formula:C19H14BrF3N2OColor and Shape:SolidMolecular weight:423.23FGFR-IN-16
CAS:<p>FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.</p>Formula:C30H27Cl2N7O4Color and Shape:SolidMolecular weight:620.49WS-11
CAS:<p>WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.</p>Formula:C26H22FN9O2Color and Shape:SolidMolecular weight:511.51BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formula:C18H15N3O2Color and Shape:SolidMolecular weight:305.331FGFR-IN-15
<p>FGFR-IN-15 (compound 18i) acts as a pan-FGFR inhibitor, exhibiting potent inhibitory activity against FGFR1-4.</p>Formula:C22H23N5O5SColor and Shape:SolidMolecular weight:469.51c-Met-IN-2
CAS:<p>c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.</p>Formula:C24H21FN10OPurity:98%Color and Shape:SolidMolecular weight:484.49MerTK-IN-1
CAS:<p>MerTK-IN-1 (compound 31) serves as an inhibitor of MerTK, with the capability to bind to the target in vivo.</p>Formula:C23H26N8O4Color and Shape:SolidMolecular weight:478.50Dyrk1A-IN-11
CAS:<p>Dyrk1A-IN-11 (compound 166) is an effective inhibitor targeting dual-specificity tyrosine phosphorylation-regulated 1A (DYRK1A) with an EC50 of 0.0021 µM. Additionally, this compound inhibits the phosphorylation of Tau (Thr212) with an EC50 of 0.0361 µM.</p>Formula:C23H23F5N8OColor and Shape:SolidMolecular weight:522.47Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formula:C31H33Cl2FN4O5SColor and Shape:SolidMolecular weight:663.59EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.97EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColor and Shape:SolidMolecular weight:514.58EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55EG31
CAS:<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formula:C30H13Br2N3O6Color and Shape:SolidMolecular weight:671.25EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27G-744
CAS:<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Formula:C29H29N5O3SPurity:98%Color and Shape:SolidMolecular weight:527.64EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Color and Shape:SolidProtein kinase inhibitor 4
CAS:<p>Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.</p>Formula:C25H24F2N6O3SMolecular weight:526.56c-Fms-IN-15
CAS:<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>Formula:C29H28F3N7O2Molecular weight:563.57LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Color and Shape:SolidMolecular weight:413.854EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Color and Shape:SolidEGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formula:C27H29F2N7O3Color and Shape:SolidMolecular weight:537.56PF-06273340
CAS:<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Formula:C23H22ClN7O3Purity:98% - 98.00%Color and Shape:SolidMolecular weight:479.92UniPR500
CAS:<p>UniPR500, a derivative of UniPR129, is a competitive antagonist for the EphA2 receptor, with a Ki of 0.78 μM. It reduces the binding of biotinylated Ephrin-A1 to EphA2 in a dose-dependent manner, exhibiting an IC50 value of 1.1 μM.</p>Formula:C36H51N3O4Color and Shape:SolidMolecular weight:589.808VEGFR2-IN-1
CAS:<p>VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.</p>Formula:C22H18N6SPurity:98.15%Color and Shape:SolidMolecular weight:398.48EGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formula:C27H31N7O3Color and Shape:SolidMolecular weight:501.58AMG-25
CAS:<p>AMG-25 (c-Kit-IN-5-1) is a c-Kit inhibitor that inhibits c-Kit, KDR, p38, Lck, and Src, and can be used for the study of mast cell-associated fibrotic diseases.</p>Formula:C23H17N5O2Purity:98.16%Color and Shape:SolidMolecular weight:395.41EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formula:C19H21N3O2SColor and Shape:SolidMolecular weight:355.45NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34DDR1-IN-10
CAS:<p>DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.</p>Formula:C24H25F4N5O2Color and Shape:SolidMolecular weight:491.481DDR1/2 inhibitor-3
CAS:<p>DDR1/2 inhibitor-3 (5n) is an inhibitor of DDR1/2, with IC50 values of 9.4 nM and 20.4 nM, respectively. It is applicable in anti-inflammatory research.</p>Formula:C31H31F3N6OColor and Shape:SolidMolecular weight:560.613JBJ-09-063
CAS:<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Formula:C31H29FN4O3SColor and Shape:SolidMolecular weight:556.65ONO-7579
CAS:<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Formula:C24H18ClF3N6O4SColor and Shape:SolidMolecular weight:578.95
